Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
Over 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60–70% two or more NPS are present. Their incidence is important in terms of prognosis and severity of pathology. However, among all NPS, apathy is often the most disturbing, associated with greater caregiver’s burden....
Saved in:
| Main Authors: | Rita Moretti, Paola Caruso, Matteo Dal Ben |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2017/6219851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Apathy and Related Executive Syndromes in Dementia Associated with Parkinson’s Disease and in Alzheimer’s Disease
by: Dario Grossi, et al.
Published: (2013-01-01) -
Apathy in Frontotemporal Dementia: Behavioral and Neuroimaging Correlates
by: Paul J. Eslinger, et al.
Published: (2012-01-01) -
Improvement of apathy in early Parkinson’s disease
by: A. Castrioto, et al.
Published: (2025-04-01) -
Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia
by: Karima Schwab, et al.
Published: (2025-01-01) -
Functional and microstructural neurosubstrates between apathy and depressive symptoms in dementia
by: Sheng-Min Huang, et al.
Published: (2025-01-01)